These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24991796)

  • 1. Reply: dissociating angiotensin 1-9 anticardiovascular remodeling effects from those on blood pressure.
    Ocaranza MP; Michea L; Chiong M; Lavandero S; Jalil JE
    J Hypertens; 2014 Aug; 32(8):1719-21. PubMed ID: 24991796
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissociating angiotensin 1-9 anticardiovascular remodeling effects from those on blood pressure.
    Calò LA; Davis PA
    J Hypertens; 2014 Aug; 32(8):1718-9. PubMed ID: 24991795
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis.
    Ocaranza MP; Moya J; Barrientos V; Alzamora R; Hevia D; Morales C; Pinto M; Escudero N; García L; Novoa U; Ayala P; Díaz-Araya G; Godoy I; Chiong M; Lavandero S; Jalil JE; Michea L
    J Hypertens; 2014 Apr; 32(4):771-83. PubMed ID: 24463937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor.
    Regulska K; Stanisz B; Regulski M; Murias M
    Drug Discov Today; 2014 Nov; 19(11):1731-1743. PubMed ID: 24997281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular remodeling and its correction: toward a comprehensive strategy.
    Bühler FR; Laragh JH; Holzgreve H
    Am J Med; 1993 Apr; 94(4A):1S-3S. PubMed ID: 8488850
    [No Abstract]   [Full Text] [Related]  

  • 6. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system.
    Lautner RQ; Villela DC; Fraga-Silva RA; Silva N; Verano-Braga T; Costa-Fraga F; Jankowski J; Jankowski V; Sousa F; Alzamora A; Soares E; Barbosa C; Kjeldsen F; Oliveira A; Braga J; Savergnini S; Maia G; Peluso AB; Passos-Silva D; Ferreira A; Alves F; Martins A; Raizada M; Paula R; Motta-Santos D; Klempin F; Pimenta A; Alenina N; Sinisterra R; Bader M; Campagnole-Santos MJ; Santos RA
    Circ Res; 2013 Apr; 112(8):1104-11. PubMed ID: 23446738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
    Liao Y; Husain A
    Can J Cardiol; 1995 Aug; 11 Suppl F():13F-19F. PubMed ID: 7664213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The renin-angiotensin system in hypertension and heart insufficiency: current aspects in the use of ACE inhibitors].
    Greminger P; Vetter W
    Schweiz Rundsch Med Prax; 1988 Jun; 77(24):673-9. PubMed ID: 3041532
    [No Abstract]   [Full Text] [Related]  

  • 11. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
    Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
    Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
    Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of angiotensin II-angiotensin-(1-7) counterbalance in disease progression in spontaneously hypertensive rats treated with/without perindopril.
    Zhou X; Shang D; Zhang T; Li L; Zhou T; Lu W
    Pharmacol Res; 2012 Aug; 66(2):177-84. PubMed ID: 22513176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart.
    Mercure C; Yogi A; Callera GE; Aranha AB; Bader M; Ferreira AJ; Santos RA; Walther T; Touyz RM; Reudelhuber TL
    Circ Res; 2008 Nov; 103(11):1319-26. PubMed ID: 18845809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure].
    Francischetti EA
    Arq Bras Cardiol; 1995 Mar; 64(3):191-4. PubMed ID: 7487502
    [No Abstract]   [Full Text] [Related]  

  • 17. Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
    Johnston CI; Iansek R; Millar JA; McGrath BP; Matthews PG
    Aust N Z J Med; 1981; 11(Suppl 1):59-63. PubMed ID: 6266379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
    Regoli D; Gobeil F
    Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What have we learned about inhibitors of the renin-angiotensin system?].
    Waeber B; Nussberger J; Brunner HR
    Ann Endocrinol (Paris); 1986; 47(3):167-77. PubMed ID: 3022638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotection with angiotensin type-1 receptor blockers in hypertension.
    Narain VS; Kochar A
    Indian Heart J; 2000; 52(1):89-92. PubMed ID: 10820943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.